Please login to the form below

Not currently logged in
Email:
Password:

Merck and Co

This page shows the latest Merck and Co news and features for those working in and with pharma, biotech and healthcare.

Merck puts prostate cancer firmly in Keytruda’s sights

Merck puts prostate cancer firmly in Keytruda’s sights

Lynparza combination could open up huge new market. Merck &Co/MSD has pressed the accelerator on plans to set up Keytruda as the go-to cancer immunotherapy for prostate cancer, building ... Merck &Co's Roy Baynes. The data suggests Keytruda could

Latest news

  • Keytruda combo outshines Opdivo in kidney cancer Keytruda combo outshines Opdivo in kidney cancer

    The data sets Merck &Co up to steal market share away from it rival, and the firm has already has filed the combination with the FDA. ... The NKTR-214 Opdivo combination is a vital one for BMS as it looks for a way to keep up with Merck &Co and its

  • Chinese biotechs aim PD-L1 antibody at hepatitis B Chinese biotechs aim PD-L1 antibody at hepatitis B

    Front-runners in the immuno-oncology category such as Bristol-Myers Squibb (BMS) with Opdivo (nivolumab) and Merck &Co/MSD with Keytruda (pembrolizumab) have not started trialling their blockbuster drugs in ... Wang. BMS and Merck are both trying to

  • GSK upbeat on its return to oncology market GSK upbeat on its return to oncology market

    excellence. Can GSK make Tesaro assets shine? Analysts are sceptical that Zejula can make up ground on its biggest rival, Lynparza, the runaway market leader co-marketed by AstraZeneca and Merck ... Co, with another rival Clovis’ Rubraca, also

  • BMS and Celgene deal sparks debate on pharma profit motive, more M&A BMS and Celgene deal sparks debate on pharma profit motive, more M&A

    Two companies mentioned as potential likely buyers in the market are AbbVie and Merck &Co. ... Meanwhile Merck &Co has had enormous success with its immuno-oncology market leader Keytruda, but the rest of its portfolio is looking distinctly threadbare by

  • BMS and Celgene announce $74bn merger BMS and Celgene announce $74bn merger

    BMS and Celgene have each had their travails in recent times: BMS has seen its first-to-market immunotherapy Opdivo overtaken by Merck &Co’s rival Keytruda, while Celgene suffered numerous ... Their combination will unquestionably cause heated

More from news
Approximately 43 fully matching, plus 434 partially matching documents found.

Latest Intelligence

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    EvaluatePharma forecasts that Lynparza (now co-marketed with Merck &Co) will hit annual revenues of $2.2bn by 2024, with Imfinzi expected to reach $3.65bn and Tagrisso leading the way ... This gives it a unique niche in an IO lung cancer market dominated

  • Deal Watch October 2018

    The deal between Merck &Co and Samsung Bioepis has been in place since 2013, when Merck &Co began to work with Samsung Bioepis to produce biosimilars. ... Merck &Co has paid $155m to Samsung Bioepis to cover the investments made so far, plus interest, in

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    Checkpoint inhibitors – old and new. The first wave of checkpoint inhibitors targeting PD-(L) 1 and CTLA-4, from Bristol-Myers Squibb, Merck &Co, Roche, AstraZeneca and Merck KGaA/Pfizer, have ... Meanwhile, Incyte’s Merck &Co partnered IDO inhibitor

  • Advancing women in healthcare Advancing women in healthcare

    Taking on the mantle of HBA’s Woman of the Year 2018 is Julie Gerberding, Merck &Co’s chief patient officer, and head of global public policy and population health. ... She joined Merck &Co in 2009 and sees her role in promoting vaccines and

  • The good, the bad and the ugly The good, the bad and the ugly

    Beyond Pfizer, the biggest positive movers in the top 20 include Shire, Bayer and Merck &Co. ... 2020.”. Central Nervous System. 2017 was a quiet year in CNS. The most prominent growing companies were Merck &Co (49.8%), Takeda (39.1%) and Sumitomo

More from intelligence
Approximately 0 fully matching, plus 39 partially matching documents found.

Latest appointments

  • Weekly industry appointments Weekly industry appointments

    Laboratories and Merck &Co. ... to help take Abcam to the next stage in its development and growth.”.

  • Nabriva Therapeutics appoints chief medical officer Nabriva Therapeutics appoints chief medical officer

    Schranz. Dr Schranz joins Nabriva from Irish biopharma Shire, with nearly two decades of experience in clinical development and medical affairs. ... Her career has seen her hold positions at Shire, ViroPharma, Pfizer, GlaxoSmithKline and Merck &Co.

  • Hansa Medical poaches Vifor Pharma’s CEO Hansa Medical poaches Vifor Pharma’s CEO

    Tulstrup was most recently CEO of Swiss pharmaceutical group Vifor Pharma and prior to this he served as senior vice president, global franchise head at Shire. ... Additionally, Tulstrup has served as CEO of Santaris Pharma, now part of Roche, and in

  • Astellas promotes Anthony Fiordaliso to VP, Americas finance Astellas promotes Anthony Fiordaliso to VP, Americas finance

    He has been with the pharma company since 2010, when he joined from Schering-Plough (now part of Merck &Co) and subsequently held positions of increasing responsibility. ... In his new role Fiordaliso will report to Stephen Knowles, senior vice president

  • Intellia Therapeutics appoints Dr Moncef Slaoui and Dr Frank Verwiel Intellia Therapeutics appoints Dr Moncef Slaoui and Dr Frank Verwiel

    is establishing a Science and Technology Committee, which will be chaired by Slaoui. ... Verwiel has also served at Merck &Co, where he was vice president and was general manager at Merck Sharpe Dohme’s operations in the Netherlands.

More from appointments
Approximately 4 fully matching, plus 33 partially matching documents found.

Latest from PMHub

  • Practical Patient Centricity

    Merck &Co, Sanofi and UCB have identified the competitive advantage that patient centricity brings and are leading the way in its practical implementation. ... Patient centricity is the next market access – and will take 10 years to embed”.

  • Digital Marketing is no Substitute for Sound Strategic Marketing

    With a stronger market access focus, companies can create and implement stronger marketing strategies. ... With no prior blueprint on how to ‘go digital’ in their marketing, early pioneer companies such as Merck &Co.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics